Zurich, 28 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: 
ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that it has received notification from SIX Exchange Regulation AG {“SER”) that the trading of Achiko’s shares shall be suspended as of Tuesday, 28 June 2022.

On 27 June 2022, SER has performed an initial review of Achiko’s annual financial statements published on 26 June 2022 and determined that they do not comply with Art.49 and Art 51 of the Listing Rules1 (“LR”) requiring the Issuer to publish an annual financial report, comprising the audited annual financial statements in accordance with the applicable financial reporting standard, as well as the corresponding audit report. SER noted that the audit report included in the annual report 2021 of Achiko issues an Adverse Opinion and, based on the auditor’s conclusion, there is strong indication that the Issuer has breached Art. 49 and 51 LR, one of the most important conditions for maintaining a listing.  Therefore, SER advised that the trading of Achiko’s shares shall be suspended based on Art.57 LR as of Tuesday, 28 June 2022, until the orderly conditions are restored. Furthermore, SER has given Achiko AG a deadline until 31 July 2022 to publish audited financial statements in accordance with Art 49 and 51 LR.

As noted in the Company’s adhoc announcement of 26 June 2022, Achiko is looking forward to immediately completing a capital increase. The Company is working with its auditors, lawyers and a number of investors and financiers to resolve the situation as soon as possible and expects to be able to comply with SER’s requirement in advance of the 31 July deadline.

The Company has commenced production to supply Nahdlatul Ulama in Indonesia with its affordable, non-invasive Covid-19 saliva-based rapid test AptameX™ and this week has started supplying tests to 600 schools in Indonesia.  The Company is also producing samples for prospective customers in other Asian countries, the UK, Europe and The Middle East. 

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Zurich, 26 June 2022– Achiko AG (SIX: ACHI; OTCQB:  ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended 31 December 2021, and progress since then.

For the year ended 31 December 2021, the Group recorded a net loss of USD $9,231,779 resulting in an increase of the Group’s accumulated losses to USD $34,568,395.   The Company also notes that Achiko AG is currently managing creditors, and that while the assets of the Group at the reporting date was negative $4.584m, it also has over $2.4m in subordinated loans. 

As a result, the Company’s auditors have given an adverse opinion, noting the Company’s ability to remain a going concern depends on the successful approval of an increase in Authorised Capital at the upcoming General Meeting, and the support of the Company’s creditors and shareholders.

“2021 was a challenging year”, said Mr Steven Goh, Co-Founder and CEO of Achiko. “We realise that the Covid-19 challenge and for us to deliver a timely solution continues to evolve.  For some markets, there’s an optimism that the challenges Covid-19 presents may be over.  For many others, they’re finding it’s anything but.”

The Company moved to reduce costs in the last half of 2021, and encountered numerous operational challenges, including continuity of the Company’s accounting and finance function.

“From a personal standpoint, after two years being restricted in travel and movement, I’ve spent the last few months travelling including fixing production in Indonesia including review, solving issues and optimising production, managing technology development in Europe, seeing investors and working to get the Accounts out.”, added Goh. 

It’s with some irony that in the middle of audit completion, I’ve had my own Covid-19 experience.  The delays have been a continuing source of frustration, however I am confident that the Company’s accounting and finance function is now stabilized and that post reporting date we have successfully reinstitionalised financial controls and the Company’s ability to keep books and records.”

Despite the challenging environment, the Company has continued to progress the development of its core Aptamex™ technology and is positioned to capitalise on the substantial competitive benefits of its differentiated chemistry for the detection of Covid-19 and application to various other pathogens.

Post-balance date highlights include:

1. The Company reported that calibration testing of its affordable, non-invasive Covid-19 saliva-based rapid test AptameX correctly differentiated 100% of test samples up until a comparable reverse transcription polymerase chain reaction (RT-PCR) cycle threshold (CT) value of 33, indicating the system’s ability to deliver a >97% sensitive and > 97% specific rapid test at a wider range of viral loads than most other rapid tests.
2. Having secured the full approval of the optimized second-generation of AptameX with the Indonesia’s Ministry of Health for five years, Achiko, with the support of our local production partner Indopharma, secured a large-scale landmark sales deal with Nahdlatul Ulama (“NU”), one of the world’s largest membership organisations with direct reach to over 90 million people to produce 1,000,000 tests now, and on success to produce 5,000,000 or more tests per month from October 2022 onwards.
3. Successful registration of a CE Mark, enabling the Company to commence commercialisation efforts in the European Union and other geographies.

“Given the Company’s level of indebtedness, we understand and appreciate the auditor’s adverse opinion, and note that we are in agreement that the Company’s ability to remain a going concern depends on approval at the upcoming General Meeting to increase share capacity,  the continued support of shareholders, creditors, and investors,  the Company’s access to capital, and timing of sales and commercialisation efforts.  To that end, we are looking forward to immediately completing a capital increase, and to the General Meeting to expand the Company’s authorized capital.” said Goh

The Annual Report is available for download at: https://www.achiko.com/financials/.

The Annual General Meeting of shareholders will take place in July 2022 on a date to be announced in due course.

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Zurich, 20 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: 
ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual 
report and its annual financial statements for the year 2021 on 26 June 2022 at the latest. As a company listed on SIX, Achiko is required to publish its annual report, together with the annual financial statements, within four months of the balance sheet date. Due to the Covid-19 pandemic, new staffing and training under difficult conditions in consequence of measures taken by several countries required a lot of management capacity. As a result, the publication of the annual report 2021, together with the annual financial statements and the audit report, will occur in the month of June 2022. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the annual report and the annual financial statements 2021. On 28 April 2022, SER granted Achiko the requested extension.  Achiko filed a second extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 30 May 2022, SER granted Achiko the second extension. Achiko filed a third extension request with SER regarding the publication of the annual report and the annual financial statements 2021.  On 3 June 2022, SER granted Achiko the third extension. On 10 June 2022, Achiko filed a fourth extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 10 June, SER granted Achiko the fourth extension. On 20 June 2022, Achiko filed a fifth extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 20 June, SER granted Achiko the fifth extension.  The delay is a function of the matters announced previously including continuity of operations in the second half of the financial year as a result of the Covid-19 pandemic and the higher than expected manual administrative workload, in particular regarding the auditory reconciliation documentation.   In addition, the Company’s CEO contracted Covid-19 during the calendar week 23/2022 limiting his ability to compile the relevant accounting documentation swiftly and interact with others in physical meetings.

As required by SER, Achiko hereby reprints para. I of SER’s respective decision: 

“The exemption application of Achiko (Issuer) dated 20 June 2022 requesting a fifth extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG until 26 June 2022 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):    

1. SIX Exchange Regulation AG reserves the right to suspend trading of the registered shares of the Issuer in case its 2021 annual report is  not  published  in  accordance  with  the  provisions on ad hoc publicity (Art. 53 of the Listing Rules [LR] in connection with the  Directive on Ad hoc Publicity [DAH]) and not filed with SIX Exchange Regulation AG until Sunday, 26 June 2022, 11.59 pm CET, at the latest.
2. Achiko is required to publish a notice in accordance with the provisions on ad hoc publicity (art. 53 LR  in  connection with the DAH)  concerning  this  decision until  Monday 20  June  2022, 23.59 am CET, at the latest. The notice must contain: 

• the unaltered reproduction of the wording of para. I. of this decision, placed in a prominent position; 

• the reasons for the application of the Issuer requesting a fifth extension of the deadline to  publish  its  2021  annual  report  and  to  file  such  report  with  SIX  Exchange Regulation AG.” 

The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and its annual financial statements for the year 2021. 

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Zurich, 10 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the year 2021 on 20 June 2022 at the latest. As a company listed on SIX Swiss Exchange, Achiko is required to publish its annual report, together with the annual financial statements, within four months of the balance sheet date.

Due to the Covid-19 pandemic, new staffing and training under difficult conditions in consequence of measures taken by several countries required a lot of management capacity. As a result, the publication of the annual report 2021, together with the annual financial statements and the audit report, will occur in the month of June 2022. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the annual report and the annual financial statements 2021. On 28 April 2022, SER granted Achiko the requested extension.  Achiko filed a second extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 30 May 2022, SER granted Achiko the second extension. Achiko filed a third extension request with SER regarding the publication of the annual report and the annual financial statements 2021.  On 3 June 2022, SER granted Achiko the third extension. Achiko filed a fourth extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 10 June, SER granted Achiko the fourth extension.  

The delay is a result of the matters previously announced including continuity of operations in the second half of the financial year as a result of the Covid-19 pandemic and the higher than expected manual administrative workload, in particular regarding the auditory reconciliation documentation.

Ahead of the Audited Financial Statements being published, the Company advises the following unaudited key financial figures:

In an earlier announcement on 19 May 2022, the Company reported an unaudited adjusted EBITDA loss of USD$5.258m and noted the adjustments of stock-based items had yet to be completed.   The final unaudited stock-based payments (share options, interest, financing costs, etc.) is USD$2.711m and includes an interest component of USD$0.835m.  The difference between the earlier reported adjusted EBITDA loss and the final unaudited EBITDA loss of USD$8,295m is attributable to: (1) USD$0.713m in costs associated with a Swiss subsidiary and a result of retrieval of accounting records; (2) re-inclusion of director’s fees of USD$0.500m (the Board of Directors and Advisory Board fees are substantially outstanding, unpaid and majority subordinated); (3) USD$1.876m of non interest Stock based payments; and (4) other miscellaneous adjustments. 

In all, the operating losses in 2021 compared to the prior year, reflect continued investment in bringing AptameX™, to commercialisation in a challenging operating environment, and substantial cost reductions in the second half of 2021.  Given the Company’s position at year end, it’s focus was on commercialising AptameX.  To that goal, and subsequent to the end of the reporting period, the company has successfully reported in-vivo performance results of AptameX indicating a highly sensitive and highly specific test at low viral loads for Covid-19, sales and marketing agreements with the largest Islamic organisation in the world, Nahdlatul Ulama in Indonesia, updated production contracts with production partner Indofarma in Indonesia, obtaining a CE Mark enabling the Company to be able to sell AptameX in Europe, and has accepted USD$1.25m in financing in a range of equity and debt instruments.

As required by SER, Achiko hereby reprints para. I of SER’s respective decision:

“The exemption application of Achiko (Issuer) dated 10 June 2022 requesting a fourth extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG until 20 June 2022 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):

1. SIX Exchange Regulation AG reserves the right to suspend trading of the registered shares of the Issuer in case its 2021 annual  report  is  not  published  in  accordance  with  the  provisions on ad hoc publicity (Art. 53 of the Listing Rules [LR] in connection with the  Directive on Ad hoc Publicity [DAH]) and not filed with SIX Exchange AG until Monday, 20 June 2022, 11.59 pm CET, at the latest.
2. Achiko is required to publish a notice in accordance with the provisions on ad hoc publicity (art. 53  LR  in  connection with the DAH)  concerning  this  decision until  Friday, 10  June  2022, 23.59 am CET, at the latest. The notice must contain:

• the unaltered reproduction of the wording of para. I. of this decision, placed in a prominent position; 

• the reasons for the application of the Issuer requesting a fourth extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG.

• the updated unaudited key figures such Net Revenues, EBITDA, EBIT, profits/loss, balance sheet total, equity etc. for the annual results 2021.” 

The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and its annual financial statements for the year 2021. 

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Zurich, 6 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the year 2021 on 10 June 2022 at the latest. As a company listed on SIX, Achiko is required to publish its annual report, together with the annual financial statements, within four months of the balance sheet date. Due to the Covid-19 pandemic, new staffing and training under difficult conditions in consequence of measures taken by several countries required a lot of management capacity. As a result, the publication of the annual report 2021, together with the annual financial statements and the audit report, will occur in the month of June 2022. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the annual report and the annual financial statements 2021. On 28 April 2022, SER granted Achiko the requested extension.  Achiko filed a second extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 30 May 2022, SER granted Achiko the second extension. Achiko filed a third extension request with SER regarding the publication of the annual report and the annual financial statements 2021.  On 3 June 2022, SER granted Achiko the third extension. The delay is a function of the matters announced previously including continuity of operations in the second half of the financial year as a result of the COVID 19 pandemic and the higher than expected manual administrative workload, in particular regarding the auditory reconciliation documentation.

As required by SER, Achiko hereby reprints para. I of SER’s respective decision:

“The exemption application of Achiko (Issuer) dated 30 May 2022 requesting a third extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG until 10 June 2022 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):   

1. SIX Exchange Regulation AG reserves the right to suspend trading of the registered shares of the Issuer in case its 2021 annual report is not published in accordance with the provisions on ad hoc publicity (Art. 53 of the Listing Rules [LR] in connection with the Directive on Ad hoc Publicity [DAH])
2. Achiko is required to publish a notice in accordance with the provisions on ad hoc publicity (art. 53 LR in connection with the DAH) concerning this decision until Monday 6 June 2022, 11.59 pm CET, at the latest. The notice must contain:
   • the unaltered reproduction of the wording of para. I. of this decision, placed in a prominent position;
   • the reasons for the application of the Issuer requesting an extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG.”

The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and its annual financial statements for the year 2021.

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.